Cited by 275Nonmelanoma Skin Cancer StudiesHedgehog Signaling Pathway StudiesCancer and Skin Lesions

Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Open access
Bichakjian, Christopher K., Olencki, Thomas, Aasi, Sumaira Z., Alam, Murad, Andersen, James S., Berg, Daniel, Bowen, Glen M., Cheney, Richard T. +22 more·2016·Journal of the National Comprehensive Cancer Network

Abstract

Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2016.0065

Cites

231 of 231 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several guidelines indicate Mohs micrographic surgery as the first-choice treatment for cutaneous carcinomas at the ear.

    “several guidelines indicate Mohs micrographic surgery (MMS) as the first-choice treatment for cutaneous carcinomas at this site.2, 3, 4”

    From Auricular reconstruction after Mohs micrographic surgery: analysis of 101 cases (2021) · cites this paper as [3]

    The BCC-A section lists the ear as a high-risk site, and “Mohs Micrographic Surgery or Excision With Intraoperative Frozen Section Assessment” calls MMS the preferred surgical technique for high-risk basal cell carcinoma. The claim extends that recommendation to cutaneous carcinomas generally, while this guideline addresses basal cell carcinoma; its primary-treatment pathway (BCC-3) also lists standard excision as an option, so MMS is not presented as the sole first-choice treatment. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 14

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
  2. Karagas MR, Greenberg ER, Spencer SK, et al. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 1999;81:555-559.
  3. Abbas M, Kalia S. Trends in non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) in Canada: a descriptive analysis of available data. J Cutan Med Surg 2016;20:166-175.
  4. English DR, Kricker A, Heenan PJ, et al. Incidence of non-melanocytic skin cancer in Geraldton, Western Australia. Int J Cancer 1997;73:629- 633.
  5. Rosenstein BS, Phelps RG, Weinstock MA, et al. p53 mutations in basal cell carcinomas arising in routine users of sunscreens. Photochem Photobiol 1999;70:798-806.
  6. Couve-Privat S, Le Bret M, Traiffort E, et al. Functional analysis of novel sonic hedgehog gene mutations identified in basal cell carcinomas from xeroderma pigmentosum patients. Cancer Res 2004;64:3559-3565.
  7. Maloney ME, Miller SJ. Aggressive vs nonaggressive subtypes (basal cell carcinoma). In: Miller SJ, Maloney ME, eds. Cutaneous Oncology Pathophysiology, Diagnosis, and Management. Malden, MA: Blackwell Science; 1998:609-613.
  8. Salasche SJ. Features associated with recurrence (squamous cell carcinoma). In: Miller SJ, Maloney ME, eds. Cutaneous Oncology Pathophysiology, Diagnosis, and Management. Malden, MA: Blackwell Science; 1998:494-499.
  9. Boeta-Angeles L, Bennett RG. Features associated with recurrence (basal cell carcinoma). In: Miller SJ, Maloney ME, eds. Cutaneous Oncology Pathophysiology, Diagnosis, and Management. Malden, MA: Blackwell Science; 1998:646-656.
  10. Rigel DS, Robins P, Friedman RJ. Predicting recurrence of basal-cell carcinomas treated by microscopically controlled excision: a recurrence index score. J Dermatol Surg Oncol 1981;7:807-810.
  11. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma: report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984;10:1043-1060.
  12. Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma: report of five cases. Cancer 1994;73:328-335.
  13. Swanson NA, Johnson TM. Management of basal and squamous cell carcinoma. In: Cummings C, ed. Otolaryngology Head and Neck Surgery. New York: Mosby Yearbook; 1998:486-501.
  14. Jacobs GH, Rippey JJ, Altini M. Prediction of aggressive behavior in basal cell carcinoma. Cancer 1982;49:533-537.

Cited by

Sorted by citations

Authors
Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Berg, D., Bowen, G. M., Cheney, R. T., Daniels, G. A., Glass, L. F., Grekin, R. C., Grossman, K., Higgins, S. A., Ho, A. L., Lewis, K. D., Lydiatt, D. D., Nehal, K. S., Nghiem, P., Olsen, E. A., Schmults, C. D., Sekulic, A., Shaha, A. R., Thorstad, W. L., Tuli, M., Urist, M. M., Wang, T. S., Wong, S. L., Zic, J. A., Hoffmann, K. G., & Engh, A.
Affiliations
  • University of Michigan (US)
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
  • Northwestern University (US)
  • Seattle Cancer Care Alliance (US)
  • University of Utah (US)
  • Roswell Park Comprehensive Cancer Center (US)
  • University of South Florida (US)
  • University of California, San Francisco (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Colorado Cancer Center (US)
  • St. Jude Children's Research Hospital (US)
Venue
Journal of the National Comprehensive Cancer Network
Published
2016-05
Volume
14
Issue
5
Pages
574-597
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W2389343900
Cited by
275
References
231
Citations by year
2026: 7 · 2025: 14 · 2024: 23 · 2023: 33 · 2022: 37 · 2021: 44 · 2020: 32 · 2019: 38 · 2018: 30 · 2017: 11 · 2016: 4 · 2015: 1
FWCI
25.90
Type
journal article
Language
en
Open access
Locations
  • Journal of the National Comprehensive Cancer Network (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
  • Health Sciences › Medicine › Dermatology › Cancer and Skin Lesions
Keywords
basal cell carcinoma, skin cancer, surgical excision, radiotherapy, cryosurgery, photodynamic therapy, topical treatment, Hedgehog pathway inhibitors, metastatic basal cell carcinoma, recurrence, risk assessment, treatment selection
MeSH terms
Basal Cell Carcinoma, Humans, Skin Neoplasms, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review